Physician profile
James N Code, II
NPI 1982730081
$1,535.64
in general payments reported to CMS, 2019-2025
32 companies · $293 in 2025
The $293 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $117 · 2021: $92.28 · 2022: $77.88 · 2023: $278 · 2024: $536 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,089 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,089.35 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $261.47 | 2022-2025 | |
| Celgene Corporation | $260.87 | 2022-2025 | Reblozyl, Breyanzi, Opdualag |
| Daiichi Sankyo INC. | $110.05 | 2023-2025 | Enhertu, Injectafer |
| Pfizer INC. | $85.78 | 2019-2025 | |
| Astellas Pharma US INC | $85.00 | 2020 | |
| Genentech USA, INC. | $54.15 | 2019-2021 | |
| Genzyme Corporation | $53.18 | 2023-2024 | |
| Astrazeneca Pharmaceuticals Lp | $52.95 | 2020-2024 | Wainua |
| Foundation Medicine, INC. | $44.88 | 2019 | |
| Stemline Therapeutics INC. | $43.89 | 2020-2024 | Elzonris |
| E.R. Squibb & Sons, L.L.C. | $41.77 | 2024-2025 | Opdivo |
| Eisai INC. | $34.20 | 2021-2024 | |
| Abbvie INC. | $33.78 | 2024 | |
| Sobi, INC | $32.37 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $30.74 | 2024-2025 | Onivyde, Tazverik |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $30.61 | 2019-2024 | Keytruda |
| Tosoh Bioscience, INC. | $25.00 | 2019 | |
| Gilead Sciences, INC. | $24.00 | 2025 | Trodelvy |
| Glaxosmithkline, LLC. | $22.42 | 2025 | Ojjaara |
| Sun Pharmaceutical Industries INC. | $20.72 | 2023 | Yonsa, Odomzo |
| Novo Nordisk INC | $20.39 | 2023 | |
| Taiho Oncology, INC. | $20.19 | 2023 | |
| Servier Pharmaceuticals LLC | $18.01 | 2024 | |
| Pharmaessentia USA Corporation | $17.64 | 2022 | |
| Kite Pharma, INC. | $17.44 | 2025 | Yescarta |
| Amgen INC. | $17.38 | 2023 | Lumakras |
| Aveo Pharmaceuticals, INC. | $16.11 | 2023 | Fotivda |
| Secura Bio, INC. | $14.22 | 2024 | Copiktra |
| Global Blood Therapeutics, INC. | $12.65 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $11.50 | 2021 | |
| Beigene USA, INC. | $11.39 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Code listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.